SCHEMBL17540641

SCHEMBL17540641

O=C(CCl)NC(F)Cc1cccc(Br)c1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.44
ALDH1A1 P00352 1/20 0.44
NCOA1 Q15788 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
NCOA3 Q9Y6Q9 1/20 0.44
CNR1 P21554 1/20 0.43
PTGES O14684 1/20 0.41
EGFR P00533 4/20 0.40
ERBB2 P04626 4/20 0.40
SIGMAR1 Q99720 1/20 0.40
TP53 P04637 1/20 0.40
MTOR P42345 1/20 0.40
TAAR1 Q96RJ0 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CTSL P07711 1/20 0.39
CTSB P07858 1/20 0.39
CTSS P25774 1/20 0.39
CTSK P43235 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1177149 0.82 HTT (0.43) HTTALDH1A1NCOA1SMN1; SMN2NCOA3
SCHEMBL17540701 0.76 CTSB (0.38) ALDH1A1PTGESCTSLCTSBCTSS
SCHEMBL17540644 0.73 CNR1 (0.60) ALDH1A1SMN1; SMN2CNR1TAAR1
SCHEMBL30967759 0.72 ALDH1A1 (0.46) ALDH1A1PTGESSIGMAR1TAAR1CTSB
SCHEMBL29237625 0.72 ALDH1A1 (0.46) ALDH1A1PTGESSIGMAR1TAAR1CTSB
SCHEMBL28122969 0.71 ALDH1A1 (0.60) HTTALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL18498768 0.70 TAAR1 (0.50) SMN1; SMN2SIGMAR1TAAR1
SCHEMBL15505046 0.70 MAOB (0.48) CNR1PTGESSIGMAR1TAAR1
SCHEMBL3471743 0.70 HCAR2 (0.47) PTGESEGFRERBB2SIGMAR1TAAR1
SCHEMBL24528878 0.69 ACACB (0.57) PTGESSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10316036-B2 Substituted pyrazino[2,2-a]isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2019-06-11 US disclosed
EP-3186250-B1 SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS HOFFMANN LA ROCHE (CH) 2018-04-18 EP disclosed
US-20180037582-A1 SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-02-08 US disclosed
US-9828374-B2 Substituted pyrazino[2,2-a]isoquinoline derivatives HOFFMANN-LA ROCHE INC. (US) 2017-11-28 US disclosed
EP-3186250-A1 SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. Hoffmann-La Roche AG (CH) 2017-07-05 EP disclosed
US-20170145010-A1 SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2017-05-25 US disclosed
WO-2016030306-A1 SUBSTITUTED PYRAZINO[2,1-A]ISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF CNS DISORDERS F. HOFFMANN-LA ROCHE AG (CH) 2016-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170145010-A1 SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES HCRTR2, CYP11B2, CYP1A2 HTT 1608/4885ALDH1A1 255/4885NCOA1 434/4885
US-20180037582-A1 SUBSTITUTED PYRAZINO[2,2-a]ISOQUINOLINE DERIVATIVES HCRTR2, HCRTR1, CYP11B2 HTT 1262/4885ALDH1A1 352/4885NCOA1 234/4885
US-10316036-B2 Substituted pyrazino[2,2-a]isoquinoline derivatives HCRTR2, HCRTR1, CYP11B2 HTT 1262/4885ALDH1A1 352/4885NCOA1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.